3b4y
From Proteopedia
(Difference between revisions)
m (Protected "3b4y" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:3b4y.png|left|200px]] | ||
| - | |||
| - | <!-- | ||
| - | The line below this paragraph, containing "STRUCTURE_3b4y", creates the "Structure Box" on the page. | ||
| - | You may change the PDB parameter (which sets the PDB file loaded into the applet) | ||
| - | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | ||
| - | or leave the SCENE parameter empty for the default display. | ||
| - | --> | ||
{{STRUCTURE_3b4y| PDB=3b4y | SCENE= }} | {{STRUCTURE_3b4y| PDB=3b4y | SCENE= }} | ||
| - | |||
===FGD1 (Rv0407) from Mycobacterium tuberculosis=== | ===FGD1 (Rv0407) from Mycobacterium tuberculosis=== | ||
| + | {{ABSTRACT_PUBMED_18434308}} | ||
| - | + | ==Function== | |
| - | + | [[http://www.uniprot.org/uniprot/P96253_MYCTU P96253_MYCTU]] Catalyzes the coenzyme F420-dependent oxidation of glucose 6-phosphate to 6-phosphogluconolactone. Is essential for the bioreductive activation of the prodrug PA-824 (nitroimidazo-oxazine) developed for anti-tuberculosis therapy against both replicating and persistent bacteria. It does not interact directly with PA-824 but, rather, provides reduced F420 to an accessory protein (Rv3547), which in turn activates PA-824. Also probably has a role in resistance to oxidative stress, via its consumption of G6P that serves as a source of reducing power to combat oxidative stress in mycobacteria.<ref>PMID:10879539</ref><ref>PMID:18434308</ref> | |
| - | + | ||
| - | + | ||
| - | --> | + | |
| - | + | ||
==About this Structure== | ==About this Structure== | ||
| Line 22: | Line 10: | ||
==Reference== | ==Reference== | ||
| - | <ref group="xtra">PMID:018434308</ref><references group="xtra"/> | + | <ref group="xtra">PMID:018434308</ref><references group="xtra"/><references/> |
[[Category: Mycobacterium tuberculosis h37rv]] | [[Category: Mycobacterium tuberculosis h37rv]] | ||
[[Category: Baker, E N.]] | [[Category: Baker, E N.]] | ||
| Line 29: | Line 17: | ||
[[Category: Squire, C J.]] | [[Category: Squire, C J.]] | ||
[[Category: TBSGC, TB Structural Genomics Consortium.]] | [[Category: TBSGC, TB Structural Genomics Consortium.]] | ||
| + | [[Category: F420 binding]] | ||
| + | [[Category: Non-prolyl cis-peptide bulge]] | ||
| + | [[Category: Oxidoreductase]] | ||
| + | [[Category: Structural genomic]] | ||
| + | [[Category: Tb structural genomics consortium]] | ||
| + | [[Category: Tbsgc]] | ||
| + | [[Category: Tim-barrel]] | ||
Revision as of 09:19, 27 March 2013
Contents |
FGD1 (Rv0407) from Mycobacterium tuberculosis
Template:ABSTRACT PUBMED 18434308
Function
[P96253_MYCTU] Catalyzes the coenzyme F420-dependent oxidation of glucose 6-phosphate to 6-phosphogluconolactone. Is essential for the bioreductive activation of the prodrug PA-824 (nitroimidazo-oxazine) developed for anti-tuberculosis therapy against both replicating and persistent bacteria. It does not interact directly with PA-824 but, rather, provides reduced F420 to an accessory protein (Rv3547), which in turn activates PA-824. Also probably has a role in resistance to oxidative stress, via its consumption of G6P that serves as a source of reducing power to combat oxidative stress in mycobacteria.[1][2]
About this Structure
3b4y is a 2 chain structure with sequence from Mycobacterium tuberculosis h37rv. Full crystallographic information is available from OCA.
Reference
- Bashiri G, Squire CJ, Moreland NJ, Baker EN. Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. J Biol Chem. 2008 Jun 20;283(25):17531-41. Epub 2008 Apr 22. PMID:18434308 doi:10.1074/jbc.M801854200
- ↑ Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000 Jun 22;405(6789):962-6. PMID:10879539 doi:10.1038/35016103
- ↑ Bashiri G, Squire CJ, Moreland NJ, Baker EN. Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. J Biol Chem. 2008 Jun 20;283(25):17531-41. Epub 2008 Apr 22. PMID:18434308 doi:10.1074/jbc.M801854200
